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Abstract
Context:
Adipose tissue is a highly active endocrine organ that secretes many factors that affect other tissues and whole-body
 metabolism. Adipocytes are responsive to several glycoprotein 130 (gp130) cytokines, some of which have been
 targeted as potential antiobesity therapeutics.
Objective:
Oncostatin M (OSM) is a gp130 family member known to inhibit adipocyte differentiation in vitro, but its effects on
 other adipocyte properties are not characterized. The expression of OSM in white adipose tissue (WAT) has not been
 evaluated in the context of obesity. Thus, our objective was to examine the expression of adipose tissue OSM in obese
 animals and humans.
Design:
OSM expression was examined in adipose tissues from mice with diet-induced and genetic obesity and in obese humans
 as well as in fractionated adipose tissue from mice. Murine adipocytes were used to examine OSM receptor expression
 and the effects of OSM on adipocytes, including the secretion of factors such as plasminogen activator inhibitor 1 and
 IL-6, which are implicated in metabolic diseases.
Results:
OSM expression is increased in rodent and human obesity/type 2 diabetes mellitus. In humans, OSM levels correlate
 with body weight and insulin and are inversely correlated with glucose disposal rate as measured by hyperinsulinemic-
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euglycemic clamp. OSM is not produced from the adipocytes in WAT but derives from cells in the stromovascular
 fraction, including F4/80+ macrophages. The specific receptor of OSM, OSM receptor-β, is expressed in adipocytes and
 adipose tissue and increased in both rodent models of obesity examined. OSM acts on adipocytes to induce the
 expression and secretion of plasminogen activator inhibitor 1 and IL-6.
Conclusions:
These data indicate that WAT macrophages are a source of OSM and that OSM levels are significantly induced in
 murine and human obesity/type 2 diabetes mellitus. These studies suggest that OSM produced from immune cells in
 WAT acts in a paracrine manner on adipocytes to promote a proinflammatory phenotype in adipose tissue.
The IL-6 family is a group of functionally and structurally related cytokines that include IL-6, IL-11, IL-27, leukemia
 inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor, cardiotrophin-1 (CT-1), novel neurotrophin-
1/B cell stimulating factor-3 or cardiotrophin-like cytokine, and neuropoietin (NP) (reviewed in Ref. 1). Because all
 members of this family use glycoprotein 130 (gp130) as a common signal transducer that is required within their
 receptor complexes, the IL-6 family members are referred to as the gp130 cytokines. The primary signal transduction
 pathway that mediates response to gp130 cytokines is the Janus kinase/signal transducer and activator of transcription
 (STAT) pathway, which primarily activates STAT3.
The gp130 cytokines regulate a variety of biological processes, including hematopoiesis, immune responses,
 inflammation, stem cell potency, cardiovascular action, and neuronal survival (reviewed in Ref. 2). Circulating levels of
 many gp130 cytokines, namely IL-6, CT-1, LIF, and OSM, have been observed in humans (3,–9). Although the actions
 of this cytokine family in white adipose tissue (WAT) have not been fully elucidated, some gp130 cytokines, including
 ciliary neurotrophic factor and IL-6, have been targeted as potential therapeutic strategies in the treatment of obesity
 (10). Some gp130 cytokines can exert profound effects on WAT, body weight, and glucose and lipid metabolism in
 rodents and humans (11,–20). WAT and its primary constituents, adipocytes, are highly responsive to gp130 cytokines
 (19, 21,–25), but the effects of these cytokines in adipose tissue have not been fully elucidated.
An important function of adipose tissue includes the production and secretion of factors (adipokines) that mediate
 whole-body metabolism. Several WAT-derived factors have been investigated and shown to modulate physiological
 systems as well as insulin resistance, inflammation, and other pathological conditions (reviewed in Ref. 26). WAT is a
 source of at least 2 gp130 cytokines, IL-6 (27, 28) and CT-1 (7). In obesity, the expansion of adipose tissue can be
 accompanied by a dysregulation of adipocyte function and alterations in adipokine secretion that can contribute to the
 development of metabolic diseases (reviewed in Ref. 29). Obesity is often associated with a state of chronic low-grade
 inflammation, mediated in part by macrophage infiltration in adipose tissue (30), and increased expression and
 secretion of proinflammatory cytokines that contribute to insulin resistance and type 2 diabetes mellitus (T2DM)
 (reviewed in Ref. 31). To enhance our understanding of the potential role of cytokines in the pathogenesis of obesity
 and related disorders, we have focused on the expression and function of gp130 cytokines in adipose tissue.
OSM is a gp130 cytokine that shares substantial sequence identity with LIF (32, 33). Although originally identified for
 its ability to inhibit cancer growth in humans (34), OSM can modulate a variety of biological processes. However,
 unlike other gp130 cytokines, OSM has its own specific receptor that heterodimerizes with gp130 (35), and this
 receptor, OSM receptor-β (OSMRβ), mediates most OSM effects. OSM can regulate inflammatory responses and is
 produced by activated T cells and macrophages (34, 36, 37). OSM can suppress inflammation in murine models of
 chronic inflammatory disease such as rheumatoid arthritis and multiple sclerosis (reviewed in Ref. 38). Elevated OSM
 levels are found in inflammatory diseases in humans, including rheumatoid arthritis and atherosclerosis (39, 40). OSM
 can also regulate developmental and regenerative processes in the liver (41,–43).
Previous studies have shown that murine adipocytes in vitro and WAT in vivo are responsive to OSM (44), and
 importantly, this cytokine can inhibit preadipocyte differentiation (25, 45). Cytokines that inhibit adipogenesis, such as
 TNFα and interferon-γ, tend to have metabolically unfavorable effects such as the induction of insulin resistance
 (reviewed in Ref. 46). One study suggests OSM can attenuate adiponectin expression in human adipocytes (47).
 Overall, the role of OSM in the pathogenesis of obesity and related metabolic diseases is not understood. Nevertheless,
 recent studies by Komori et al (48) suggest a potential metabolically protective role for the OSM receptor, because
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 mice with a global depletion of OSMRβ exhibited obesity, insulin resistance, and adipose tissue inflammation.
 However, our studies suggest that OSM has negative effects on adipocytes.
Our results demonstrate for the first time that OSM mRNA and protein levels are elevated in obese/T2DM mice and
 humans. In addition, we observed a potential relationship between OSM expression and body mass index (BMI) in
 human WAT. Interestingly, OSM is present in nonadipocyte cells of human adipose tissue. In mice, OSM is present in
 both Cd11c+ and Cd11c− macrophages that are F4/80+ and found in adipose tissue of wild-type and ob/ob mice.
 OSMRβ is highly expressed in adipocytes, and its levels are increased in ob/ob mice and high-fat diet (HFD)-fed mice
 compared with appropriate controls. We also observed that OSM induces PAI-1 secretion. In addition to body weight,
 increased OSM levels correlate with insulin levels and have a negative association with glucose disposal rates in a
 small human study. Collectively, our data suggest that adipose tissue-derived OSM may be a factor in metabolic
 disease states.
Materials and Methods
Materials
DMEM was purchased from Sigma. Bovine and fetal bovine sera were purchased from Hyclone. Mouse recombinant
 OSM, CT-1, NP, and TNFα and mouse PAI-1, OSM, and OSMRβ antibodies were purchased from R&D Systems.
 Antibodies directed against human OSM, STAT5A, peroxisome proliferator-activated receptor-γ, F4/80, and the ERK
 antibodies were all purchased from Santa Cruz Biotechnology. Mouse recombinant LIF was purchased from BD
 Transduction. Adiponectin polyclonal antibody was from Affinity Bioreagents. Monocyte chemoattractant protein-1
 (MCP-1) rabbit polyclonal antibody was from Cell Signaling. CT-1 antibody was from Calbiochem. Trizol was from
 Invitrogen. Nitrocellulose was purchased from Bio-Rad. The BCA kit and the enhanced chemiluminescence kit were
 from Pierce. Horseradish peroxidase-conjugated secondary antibodies were from Jackson ImmunoResearch
 Laboratories.
Mice
Animals used for this study included genetically obese male B6.V-Lepob/J (B6-ob/ob) mice and their lean littermates as
 well as C57BL/6J mice rendered obese by dietary intervention and their lean controls. All mice were housed by the
 supplier (The Jackson Laboratory) until shipment 1 to 2 weeks before tissue harvest. B6-ob/ob mice and lean
 littermates were purchased for experimentation at 6 weeks of age and given free access to standard laboratory chow.
 C57BL/6J mice subjected to diet-induced obesity were fed an HFD consisting of 60% kcal from fat (Research Diets
 Inc; D12492) from 6 weeks of age. Lean C57BL/6J control mice were fed a control diet consisting of 10% kcal from fat
 (Research Diet Inc; D12450B) from 6 weeks of age. Both diets contained 10% kcal from protein with the balance in
 caloric intake provided by differences in carbohydrate content. Mice receiving both diets were given free access to food
 and shipped for experimentation at 11 weeks of age. All animals were euthanized by CO2 gas asphyxiation, and tissues
 were collected for total RNA or whole-tissue extract isolation. Animal care and use was approved by the Institutional
 Animal Care and Use Committee at Pennington Biomedical Research Center (PBRC). All animal studies were
 conducted with 4 to 7 mice in each group.
Cell culture
Murine 3T3-L1 preadipocytes were grown to 2 days after confluence in DMEM with 10% bovine serum. Medium was
 changed every 48 hours. A cocktail containing 0.5 mmol/L 3-isobutyl-methylxanthine, 1 μmol/L dexamethasone, and
 1.7 μmol/L insulin was used to induce preadipocytes differentiation in DMEM containing 10% fetal bovine serum.
 After 48 hours, the medium was replaced by DMEM with 10% fetal bovine serum.
Human subjects and adipose tissue biopsies
All procedures and protocols were reviewed and approved by PBRC or Indiana University Institutional Review Boards.
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 Subcutaneous adipose tissues were obtained with informed written consent from healthy nondiabetic subjects
 undergoing elective liposuction surgery. For fractionation, lipoaspirates were washed in PBS, digested in PBS
 supplemented with 1% BSA, 0.1% collagenase type II (Worthington, Lakewood, NJ), and 2mM calcium chloride for
 60 minutes with rocking at 37°C. The tissue digest was centrifuged at 300g for 5 minutes at room temperature to
 separate the floating mature adipocytes from the stromovascular fraction (SVF) cell pellet. For RNA analysis, sc
 adipose tissue was collected from the abdomen (5 cm to left/right of the umbilicus) using a Bergstrom needle in
 compliance with standard clinical practice at PBRC. Subjects undergoing bariatric surgery had approximately 20 g of
 visceral adipose tissue extracted laparoscopically while under anesthesia.
RNA isolation from cells and tissue
RNA from 100 mg of tissue was isolated by column purification (QIAGEN) and yield determined by
 spectrophotometry (NanoDrop Technologies). From each RNA sample, 200 ng was reverse transcribed to cDNA using
 the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). Relative quantification of mRNA expression
 was analyzed using ABI PRISM 7900 (Applied Biosystems). Mouse primers came from Integrated DNA Technologies,
 and the sequences were as follows: PAI-1 forward, CGGCACAACCCGACAGAGACA; PAI-1 reverse,
 TCCGAGGTCTGGGATGCTGGT; OSM forward, AGGCACGGGCCAGAGTACCA; OSM reverse,
 GGCGGATATAGGGCTCCAAGAGTG; OSMRβ forward, CGTTCCCCTGTGAGGCCGAG; OSMRβ reverse,
 TCCTCCAAGACTTCGCTTCGGG; MCP1 forward, GCAGAGAGCCAGACGGGAGGA; MCP1 reverse,
 TGGGGCGTTAACTGCATCTGG; IL6 forward, TCCTCTCTGCAAGAGACTTCCATCC; IL6 reverse,
 AAGCCTCCGACTTGTGAAGTGGT; ADPN forward, AAAAGGGCTCAGGATGCTACTG; ADPN reverse,
 TGGGCAGGATTAAGAGGAACA; PPIA (cyclophilin A) forward, CCACTGTCGCTTTTCGCCGC; PPIA
 (cyclophilin A) reverse, TGCAAACAGCTCGAAGGAGACGC; and GAPDH forward,
 TTCCAGGAGCGAGACCCCAC; GAPDH reverse, TTCAAGTGGGCCCCGGCCTT. For human RNA, custom
 TaqMan gene expression microfluidic cards for OSM (Hs00968300_g1) were used. Samples were run in triplicate, and
 expression levels were normalized to cyclophilin B (Hs00168719_m1).
Adipose tissue macrophage isolation
SVF isolated from mouse adipose tissue samples were cooled on ice, centrifuged at 500g for 5 minutes, and
 resuspended in fluorescence-activated cell sorting (FACS) buffer at a concentration of 7 × 106 cells/mL. Cells were
 incubated in the dark at 4°C on a bidirectional shaker for 30 minutes in FcBlock (20 μg/mL) (BD Pharmingen) and then
 for an additional 50 minutes with fluorophore-conjugated primary antibodies or isotype control antibodies. After
 incubation with primary antibodies, 1 mL FACS buffer was added to the cells. Cells were centrifuged at 500g for 5
 minutes and resuspended in 1 mL FACS buffer. The wash was repeated twice. Cells were analyzed on a FACSCalibur
 and analysis was performed using CellQuest software (Becton, Dickinson and Co).
Gel electrophoresis and immunoblotting
Proteins were separated in 7.5% or 10% polyacrylamide gels containing sodium dodecyl sulfate and transferred to
 nitrocellulose membrane (Bio-Rad) in 25 mmol/L Tris, 192 mmol/L glycine, and 20% methanol. After transfer, the
 membrane was blocked in 4% milk for 1 hour at room temperature and incubated with primary antibody overnight at
 4°C. Results were visualized with horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch
 Laboratory) and enhanced chemiluminescence (Pierce).
Statistical analysis
Results are expressed as mean ± SEM. Differences between specified groups were analyzed using the Student's t test
 (two-tailed) for comparing 2 groups with P < .05 considered statistically significant.
Results
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Epididymal adipose tissue from 6-week-old ob/+ and ob/ob mice was used to isolate total RNA or to obtain whole-
tissue extracts for Western blot analysis. As shown in Figure 1A, the levels of OSM and OSMRβ mRNA were increased
 in adipose tissue from ob/ob mice compared with lean littermates. We also observed a modest decrease in CT-1 mRNA
 in the obese mice. As expected, we observed statistically significant increases in IL-6, TNFα, and MCP-1 and a decline
 in adipsin mRNA in ob/ob mice. An analysis of OSM protein levels revealed a notable increase in adipose tissue from
 ob/ob mice compared with lean littermates. The expression of STAT5A is shown as a protein loading control. Similar
 data were observed in epididymal adipose tissue obtained from 18-week-old mice fed a HFD for 12 weeks (Figure 1C).
 In this study, C57BL/6J mice fed a HFD had significant increases in OSM and OSMRβ mRNA levels compared with
 mice fed a low-fat diet over the same period. There was no change in LIF mRNA levels and a modest decline in CT-1
 mRNA levels. As expected, we observed statistically significant increases in mRNA of IL-6, TNFα, and MCP-1 and a
 decline in adipsin mRNA in samples from the HFD mice. Because we observed some nonspecific bands when
 performing Western blot analysis on adipose tissue extracts from the feeding study, we performed an
 immunoprecipitation with an OSM antibody and examined the immunoprecipitated extract with a different OSM
 antibody. As shown in both lighter and darker exposures in Figure 1D, we observed a substantial increase in OSM
 protein levels in HFD. Western blot analysis of these extracts also revealed an expected increase in MCP-1 protein
 levels.
To determine whether the induction in OSM expression also occurred in human fat tissue in conditions of obesity, we
 examined the expression of OSM protein from subjects with BMIs ranging from 19.5 to 80.3. As shown in Figure 2,
 there were very low levels of OSM protein in BMIs ranging from 19.5 to 25.3. However, over a BMI range of 40.8 to
 80.3, there was a significant increase in the expression of OSM protein. To follow up on these intriguing results, we
 examined OSM expression in adipose tissue samples from morbidly obese individuals that were candidates for gastric
 bypass surgery. We had access only to samples taken at the time of surgery. As shown in Figure 3A, we detected
 elevated OSM mRNA levels in omental and mesenteric fat. We also observed an increase in OSM mRNA levels from
 sc adipose tissue in the obese group when compared with lean. Clinical data from these patients were used to search for
 potential correlations, and in our limited study of 8 female patients, we observed that sc OSM mRNA levels correlated
 with insulin levels (Figure 3C) and body weight (Figure 3D). The results in Figure 3B also indicate OSM mRNA was
 inversely correlated with glucose disposal rate. We did not observe any significant correlations with OSMRβ
 expression and body weight, insulin levels, or GDR in these subjects (data not shown).
Adipose tissue is composed of a variety of cell types, and many cytokines produced in adipose tissue are made in
 immune cells and not in adipocytes. We fractionated human adipose tissue from 2 obese subjects into adipocytes and
 the other cells present, commonly referred to as the SVF. As shown in Figure 4A, we observed that OSM was primarily
 expressed in the SVF. In contrast, CT-1, another gp130 cytokine, was expressed in both adipocytes and SVF cells.
 Adiponectin was examined as a positive control restricted solely to adipocyte expression, and STAT5A was examined
 to demonstrate protein loading in both the adipocytes and SVF cells. We also looked for the presence of OSM in
 cultured adipocytes and were unable to detect OSM secretion from adipocytes (Supplemental Figure 1, published on
 The Endocrine Society's Journals Online website at http://jcem.endojournals.org). OSM is known to be expressed in
 hematopoietic organs and is found in various immune cell types, including macrophages (49, 50). Hence, we examined
 the expression of OSM mRNA in adipose tissue macrophages (ATMs) from 4 independent cohorts of male C57BL/6
 lean and ob/ob mice at 14 weeks of age. FBC represents ATMs that are F4/80+, CD11b+, and CD11c+. FB represents
 ATMs that are F4/80+, CD11b+, and CD11c−. These results clearly demonstrate the expression of OSM in both types of
 ATMs. Also, there was a modest decrease in OSM mRNA in FBC compared with FB in ob/ob mice (Figure 4B).
Because adipocytes are highly responsive to OSM and this cytokine is known to primarily use the OSMRβ, we
 examined the expression of this highly specific OSM receptor over a time course of adipocyte differentiation in 3T3-L1
 cells. As shown in Supplemental Figure 2A, OSMRβ mRNA and protein levels are nearly equivalent in both
 preadipocytes and mature adipocytes. The efficacy of adipogenesis is shown in Supplemental Figure 2B by examining
 peroxisome proliferator-activated receptor-γ expression. Of note, we did observe an increase in OSMRβ levels during
 the clonal expansion of adipogenesis. We also examined expression of OSMRβ in a variety of murine tissues. OSMRβ
 is highly expressed in brown and white adipose tissue (Supplemental Figure 2C). These results clearly indicate that
 expression of OSMRβ is present in adipocytes in vitro and adipose tissue in vivo.
To date, few studies have focused on the actions of OSM on adipocytes. Because many cell types are present in adipose
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 tissue, we examined the effects of OSM on fully differentiated murine 3T3-L1 adipocytes. As shown in Figure 5, OSM
 and TNFα induce PAI-1 and IL-6 mRNA in adipocytes. However, the effects of both of these cytokines results in an
 effect that is at least additive, suggesting these cytokines mediate their effect via independent mechanisms. OSM also
 induces MCP-1 mRNA levels in mature adipocytes, but the induction is stronger with TNFα. TNFα also inhibits
 adiponectin mRNA expression, but we did not observe any effects of OSM on adiponectin levels in the presence or
 absence of TNFα. Next, we examined the effects of several gp130 cytokines on the secretion of 2 known adipokines,
 MCP-1 and PAI-1, from murine adipocytes. As shown in Figure 6A, all of the gp130 cytokines examined (CT-1, LIF,
 OSM, and NP) resulted in an induction of MCP-1 secretion. However, only OSM resulted in a robust increase in PAI-1
 secretion. To assess whether this response was directly regulated by OSM, we treated mature adipocytes for 90 minutes
 with various doses of OSM. Acute OSM treatment resulted in a dose-dependent increase in PAI-1 mRNA levels
 (Figure 6B) and in the phosphorylation of OSMRβ, gp130, and STAT3 (data not shown).
Discussion
Adipose tissue is highly sensitive to several gp130 cytokines, including OSM (44). Also, OSM inhibits adipocyte
 differentiation in vitro (25, 45). In these studies, we observed that OSM mRNA and protein levels are increased in 2
 rodent models of obesity/T2DM. In human studies, OSM protein was detectable in human adipose tissue and OSM
 expression was elevated in WAT obtained from individuals with BMI >40. We also analyzed fat tissue obtained from
 patients before gastric bypass surgery and observed that OSM mRNA levels are higher in omental and mesenteric fat
 when compared with sc fat tissue. In addition, in the restricted number of samples we were able to analyze, OSM levels
 in sc fat in women correlated with weight and insulin levels and had an inverse correlation with glucose disposal rates.
 Although this analysis was limited to 8 subjects, the overall modulation of OSM in human fat samples correlates with
 the increased expression of OSM mRNA and protein levels we observed in both ob/ob and HFD mice. Although further
 validation will be needed to identify human phenotypes associated with OSM expression, our observations suggest that
 OSM levels are increased in adipose tissue in conditions of obesity. Future investigations will be needed to determine
 whether OSM and its receptor are affected by gender, race, and/or age.
Our in vitro studies in cultured 3T3-L1 adipocytes and in vivo analyses in rodent and human adipose tissue support a
 working model whereby OSM is produced in adipose tissue in conditions of excess adiposity. Our results suggest that
 OSM is not produced by or secreted from adipocytes but is expressed in 2 F4/80+ populations of macrophages that are
 CD11c+ and CD11c−. Although we observed a significant increase in OSM mRNA and protein in mouse and human
 adipose tissue with obesity, we did not observe this same pattern of OSM mRNA regulation in either population of
 F4/80+ adipose tissue macrophages (Figure 4B). These results suggest that OSM is likely produced in additional
 nonadipocyte cells present in adipose tissue, and further studies are necessary to identify all of the cellular sources of
 OSM in adipose tissue. We hypothesize that nonadipocyte-derived OSM acts in a paracrine manner on adipocytes to
 promote metabolic dysfunction. Our data showing that OSM induces IL-6 and PAI-1 in a manner similar to TNFα
 support this hypothesis. OSM also induces MCP-1, but not to the same level as TNFα exposure. Although there is some
 evidence that OSM can inhibit adiponectin expression (47), we were unable to observe this effect. The discrepancy in
 our results and the published study (47) can likely be attributed to cells that were not fully differentiated adipocytes. We
 and others have shown that OSM inhibits adiponectin and other proteins that are highly expressed during adipogenesis
 in vitro. Conversely, all of our studies were performed in fully differentiated mature adipocytes.
Our results also indicate that OSM is distinct from other gp130 cytokines that use the Janus kinase/STAT signaling
 pathway in adipocytes. As shown in Figure 6, exposure to OSM, but not other gp130 cytokines, increased secretion of
 PAI-1 from cultured adipocytes. PAI-1 is known to be secreted from adipocytes and upregulated in conditions of
 obesity/T2DM (reviewed in Ref. 51). Previous studies have also shown that PAI-1 expression is induced by OSM in
 human preadipocytes and adipocytes isolated from sc and visceral adipose tissue (52) and in human coronary artery and
 aortic cells (53). PAI-1 is also known to have profound effects on tissue fibrosis (reviewed in Ref. 54). Elevated OSM
 in adipose tissue may contribute to fibrosis, in part by modulation of PAI-1. Overall, our observations suggest that
 nonadipocyte-derived OSM acts in a paracrine manner on adipocytes to promote the induction of IL-6, MCP-1, and
 PAI-1.
A very recent study examined the phenotype of mice that lack the specific OSM receptor, OSMRβ. These studies
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 showed that OSMRβ-null mice had mature-onset obesity and insulin resistance (48). Moreover, administration of OSM
 increased insulin sensitivity and polarized macrophages to an M2 phenotype. The conclusion from these studies was
 that OSM suppresses the development of insulin resistance. This study contrasts with our current observations. One
 difference between our studies is that they showed OSM mRNA was present at equivalent levels in both the SVF and
 adipocyte fractions of adipose tissue. Our studies failed to detect OSM in cultured murine adipocytes, and fractionation
 of adipose tissue revealed that most OSM protein was present in the SVF (Figure 4A). The other study did not observe
 OSMRβ in adipocytes, although we have substantial data documenting the presence of OSMRβ in mature adipocytes
 (Supplemental Figure 2B). Moreover, rodent adipose tissue in vivo is highly responsive to OSM exposure (44),
 indicating that the OSMRβ is present in adipocytes. We also observed an increase in OSMRβ in the 2 rodent models of
 obesity we examined (Figure 1), raising the possibility that adipocytes might be more sensitive to OSM under these
 conditions. Our model supports a role of OSM in inducing the expression of genes associated with inflammation and
 insulin resistance. Therefore, we hypothesize that adipose tissue-derived OSM promotes a metabolically unfavorable
 phenotype. We predict that OSMRβ signaling in adipocytes is likely involved in the pathogenesis of T2DM but does
 not serve in a protective capacity as recently suggested in mice that have a global knockout of the OSM receptor (48).
 Studies in liver indicate that OSM, produced in Kuppfer cells, can promote hepatic insulin resistance by inhibiting
 insulin-induced Akt phosphorylation (55). There is little question that many additional studies will be necessary to
 identify all the adipose tissue sources of OSM and to determine the overall function of this cytokine in T2DM.
 Nonetheless, our results clearly demonstrate that OSM levels are induced in murine and human obesity, and OSM can
 modulate adipocyte gene expression in a manner that is similar, but distinct, from TNFα.
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Footnotes
Abbreviations:
ATM
adipose tissue macrophage
BMI
body mass index
CT-1
cardiotrophin-1
FACS
fluorescence-activated cell sorting
gp130
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glycoprotein 130
HFD
high-fat diet
LIF
leukemia inhibitory factor
MCP-1
monocyte chemoattractant protein-1
NP
neuropoietin
OSM
oncostatin M
OSMRβ
OSM receptor-β
PBRC
Pennington Biomedical Research Center
STAT
signal transducer and activator of transcription
SVF
stromovascular fraction
T2DM
type 2 diabetes mellitus
WAT
white adipose tissue.
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OSM mRNA and protein levels are increased in adipose tissue of leptin-deficient mice and HFD-fed mice. A, Relative
 mRNA abundance was assessed in epididymal fat pads of male 6-week-old lean (ob/+) and leptin-deficient (ob/ob)
 mice. Data were normalized to 18S, and differences between lean and obese animals were determined via Student's t
 test where a P value of < .05 was considered significant. B, Whole-tissue extracts were prepared from epididymal
 adipose tissue, and 100 μg of protein was used for Western blot analysis to examine OSM protein levels. C, Relative
 mRNA abundance was assessed in epididymal fat pads of male mice fed a low-fat diet (LFD) or HFD for 12 weeks.
 Data were normalized to 18S, and differences between lean and obese animals were determined via Student's t test
 where a P value of <.05 was considered significant. D, Whole-tissue extracts were prepared from epididymal adipose
 tissue, and 100 μg of protein was used for Western blot analysis to examine OSM protein levels. Abbreviations: IP,
 immunoprecipitation; WB, Western blot.
Figure 2.
OSM levels are increased with higher BMI in sc human adipose tissue. Frozen human adipose tissue samples were
 obtained and used to prepare whole-tissue extracts. These were subjected to Western blot analysis for human OSM. The
 expression of STAT5 was examined to demonstrate equivalent protein loading for each sample. The results were
 visualized with horseradish peroxidase-conjugated secondary antibodies and chemiluminescence.
Figure 3.
OSM mRNA in adipose tissue depots and correlations with body weight, insulin levels, and glucose disposal rate (GDR)
 in humans. A, Different depots of human adipose tissue were obtained before gastric bypass surgery, and RNA was
 extracted and processed for OSM mRNA analysis. The results are expressed as mean values ± SEM. Lowercase letters
 represent statistical differences of P < .05. B–D, Subcutaneous adipose tissue from different patients was processed for
 mRNA analysis. Euglycemic clamp was used for assessment of GDR in these patients. Glucose disposal rate
 (milligrams per minute per kilogram) was calculated from the high dose of a 5-hour 2-step euglycemic (120 mg/dL),
 hyperinsulinemic (last 30 minutes of 2.5 hours of 400 mU/m2·min insulin infusion after 2.5 hours at 50 mU/m2·min).
 Body weight and blood insulin levels were also measured. Abbreviations: AT, adipose tissue; AU, arbitrary units;
 Mesent, mesenteric; Sub, sc; PPIA, cyclophilin A.
Figure 4.
OSM is present in nonadipocyte cells of human WAT. A, Human adipose tissue was obtained and processed to separate
 adipocytes from the SVF as described in Materials and Methods. From each sample 100 μg was separated by SDS-
PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. B, ATMs from 4 independent cohorts of
 male C57/BL6 lean and ob/ob mice at 14 weeks of age were isolated as indicated in Materials and Methods. FBC
 represents ATMs that are F4/80+, CD11b+, and CD11c+. FB represents ATMs that are F4/80+, CD11b+, and CD11c−.
Figure 5.
OSM and TNFα induce PAI-1, MCP-1, and IL-6 mRNA in murine adipocytes. Fully differentiated 3T3-L1 adipocytes
 were treated with 1nM TNFα, 1nM OSM, or both cytokines for 72 hours before harvesting. RNA was extracted and
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 processed for PAI-1 (A), IL-6 (B), MCP-1 (C), and ADPN (D) mRNA measurement. Each figure represents an
 experiment independently performed 3 times. The results are expressed as mean values ± SEM. Lowercase letters
 represent statistical differences (P < .05).
Figure 6.
OSM induces PAI-1 secretion from murine adipocytes. A, Fully differentiated 3T3-L1 adipocytes were treated with
 1nM of the various cytokines indicated in the figure. CTL represents untreated control cells. The mature adipocytes
 were treated daily, and after 96 hours, the medium was collected and used for Western blot analysis. B, Fully
 differentiated 3T3-L1 adipocytes were treated with various doses of OSM for 90 minutes. RNA was extracted and
 processed for PAI-1 and cyclophilin mRNA measurement. Each figure represents an experiment independently
 performed 3 times. The ratio of PAI-1 to cyclophilin was calculated. Results are expressed as mean ± SEM. ****, P <
 .0001 between groups.
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